Transactions in connection with share buyback programme
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailTryg - Transactions in connection with share buyback programme
On 04 December 2024, Tryg A/S (“Tryg”) announced that the Board of Directors had decided to initiate a share buyback programme of up to DKK 2.0 billion. The share buyback programme is executed in accordance with EU Market Abuse Regulation, EU Regulation no. 596/2014 of 16 April 2014 and the provisions of Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Regulation”). The share buyback programme will end no later than 30 June 2025.
Transactions made under the share buyback programme will be announced through Nasdaq Copenhagen on a weekly basis.
The following transactions have been executed in the period 17 February 2025 to 21 February 2025:
| Number of shares | Avg. purchase price, DKK | Transaction value, DKK | |
| 17 February 2025 | 110,000 | 150.33 | 16,536,300 |
| 18 February 2025 | 110,000 | 150.48 | 16,552,800 |
| 19 February 2025 | 115,000 | 149.78 | 17,224,700 |
| 20 February 2025 | 125,000 | 148.86 | 18,607,500 |
| 21 February 2025 | 125,000 | 149.95 | 18,743,750 |
| Accumulated for the period | 585,000 | 87,665,050 | |
| Accumulated under the programme | 6,995,787 | 1,056,927,654 |
Detailed information on all transactions under the share buyback programme during the period is included in the attached appendix.
Following the above transactions, Tryg owns a total of 8,195,449 treasury shares corresponding to 1.330% of the total share capital.
Attachment
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026
- Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Pati
- Roche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Stock BuybackSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
